Ma Xuhui, Wu Yunteng, Zhang Tian, Song Hao, Jv Houyu, Guo Wei, Ren Guoxin
Department of Oral and Maxillofacial-Head and Neck Oncology, Shanghai Ninth People's Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai 200011, China.
Oncotarget. 2017 Jul 31;8(47):82661-82673. doi: 10.18632/oncotarget.19746. eCollection 2017 Oct 10.
mutations are frequently detected in mucosal melanomas, but their clinical significance in metastatic oral mucosal melanomas (OMM) remains unclear. The main purpose of this study was to investigate the clinical and pathological features of metastatic OMMs with mutations and the efficiency of the tyrosine kinase inhibitor imatinib in treating metastatic OMMs. We found thatresidual primary lesion and neck lymph nodes could act as independent prognostic factors in metastatic OMM patients. mutations were detected in 22 out of 139 (15.8%) metastatic OMM patients. Under chemotherapy, the overall survival (OS) of mutant patients was significantly shorter than that of wild-type patients. The Ki67 expression was significantly higher in mutant patients than in wild-type patients. In distant metastatic OMM patients with mutations, the treatment with c-Kit inhibitor resulted in a better OS. In conclusion, residual primary lesion, cervical lymph nodes and mutations act as adverse prognostic factors of metastatic OMMs. The Kit inhibitor imatinib could benefit metastatic OMM patients with mutations.
黏膜黑色素瘤中经常检测到突变，但其在转移性口腔黏膜黑色素瘤（OMM）中的临床意义仍不清楚。本研究的主要目的是调查具有突变的转移性OMM的临床和病理特征以及酪氨酸激酶抑制剂伊马替尼治疗转移性OMM的疗效。我们发现残留原发性病变和颈部淋巴结可作为转移性OMM患者的独立预后因素。139例转移性OMM患者中有22例（15.8%）检测到突变。在化疗情况下，突变患者的总生存期（OS）明显短于野生型患者。突变患者的Ki67表达明显高于野生型患者。在发生远处转移且具有突变的OMM患者中，使用c-Kit抑制剂治疗可带来更好的总生存期。总之，残留原发性病变、颈部淋巴结和突变是转移性OMM的不良预后因素。Kit抑制剂伊马替尼可使具有突变的转移性OMM患者获益。
